Registered title, quoted from ClinicalTrials.gov
Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06404697, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: women only
Registered eligibility fields
Histological or cytological confirmed primary breast carcinoma.
Inclusion criterion 3
Pathological evaluation of axillary lymph nodes post-surgery.
Inclusion criterion 8
Negative pathological surgical margins.
Inclusion criterion 11
Patients with T4 staging of the primary tumor.
Exclusion criterion 10
KPS score ≥80, with expected survival exceeding 2 years.
Inclusion criterion 9
History of malignancy within the past 5 years (excluding ductal carcinoma in situ, basal cell carcinoma, squamous cell carcinoma in situ, cervical carcinoma in situ, and in situ adenocarcinoma of the lung).
Exclusion criterion 6
Inability to initiate radiotherapy within 12 weeks post breast cancer curative surgery (breast-conserving surgery or mastectomy), or within 8 weeks post completion of adjuvant chemotherapy.
Exclusion criterion 11
Pregnant or lactating women.
Exclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06404697, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntary participation with documented informed consent.
- Females aged ≥18 years.
- Histological or cytological confirmed primary breast carcinoma.
- Clinical diagnosis of cN3c.
- Receipt of neoadjuvant therapy, guided by the attending physician and current treatment guidelines.
- Did not achieve cCR in SCLN following neoadjuvant therapy.
- Undergoing curative-intent breast cancer surgery post-neoadjuvant therapy.
- Pathological evaluation of axillary lymph nodes post-surgery.
- KPS score ≥80, with expected survival exceeding 2 years.
- Complete healing of surgical incision without complications.
- Negative pathological surgical margins.
- Availability of hormonal receptor (ER/PR), HER2, and Ki-67 status for the primary breast lesion.
- Pre-menopausal females required to practice contraception for at least one month prior to screening, maintaining contraception throughout the study and for a specified period post-study cessation.
Exclusion Criteria:
- Patients with confirmed distant metastases by pathology or imaging.
- Those who have not received neoadjuvant systemic therapy.
- Patients who have not undergone curative-intent surgery.
- Pregnant or lactating women.
- Individuals with severe non-neoplastic comorbidities affecting radiotherapy implementation.
- History of malignancy within the past 5 years (excluding ductal carcinoma in situ, basal cell carcinoma, squamous cell carcinoma in situ, cervical carcinoma in situ, and in situ adenocarcinoma of the lung).
- Simultaneous contralateral breast cancer.
- History of prior radiation therapy to the neck, chest, or ipsilateral axilla.
- Active collagen vascular disease.
- Patients with T4 staging of the primary tumor.
- Inability to initiate radiotherapy within 12 weeks post breast cancer curative surgery (breast-conserving surgery or mastectomy), or within 8 weeks post completion of adjuvant chemotherapy.
Quoted from ClinicalTrials.gov, NCT06404697, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06404697, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.